{'fraction_non_alphanumeric': 0.019700551615445233, 'fraction_numerical': 0.01103230890464933, 'mean_word_length': 4.962441314553991, 'pattern_counts': {'":': 0, '<': 2, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Effect of New Thalidomide Analogs in Acute Kidney Injury on Rats

Renal ischemia/reperfusion (I/R) injury contains multiple mechanisms involving an excessive amount of ROS that causes oxidative stress, inflammation, and rapid kidney dysfunction. This work aimed to study the ability of thalixisostere 3f on angiogenesis and antioxidant effect in I/R. There was a significant decrease in VEGF from thalix and modified thalixisostere 3f groups as compared with that of a negative control group (P < 0.001). There was a significant decrease in the mean concentration of MDA in kidney tissue obtained from thalix and thalixisostere 3f groups as compared with that of a positive control group (P < 0.001). There was a significant increase in the mean concentrations of SOD and GSH in kidney tissue of group's thalix and thalixisostere 3f groups as compared with that of a positive control group. We found that thalixisostere 3f is more effective than thalix in inhibiting the expression VEGF as pro-angiogenic factors. Molecular docking study indicated that the proper recognition of the inhibitor thalix-isostere with the conserved amino acid residues at the binding active site of VEGFR2 as one of the important enzymes to be targeted as part of antiangiogenic anticancer.